Literature DB >> 2697706

Ocular toxoplasmosis in the immunocompromised host.

G N Holland1.   

Abstract

Disseminated toxoplasmosis is a well-known complication of immunodeficiency states, including those induced by malignancies, steroid and cytotoxic drug therapy, and AIDS. In immunodeficient patients, toxoplasmic infections of the eye are less common than toxoplasmic infections of other organs for unknown reasons. When ocular toxoplasmosis does occur in the immunodeficient host, or if immunosuppressive therapy is administered to patients with active disease, widespread tissue destruction by proliferating organisms may result. Immunodeficiency alone may not be sufficient, however, to cause reactivation of encysted organisms in retinochoroidal scars. Ocular toxoplasmosis in the immunocompromised host presents difficult problems in diagnosis and management. There may be a variety of clinical lesions, including single foci of retinochoroiditis in one or both eyes, multifocal lesions, or diffuse areas of retinal necrosis. The majority of lesions do not arise from the borders of preexisting scars, which suggests that they result from acquired infection or dissemination of organisms from nonocular sites of disease. Toxoplasma gondii may infect iris, choroid, and vitreous-tissues that are not usually infected in the immunocompetent host. Ocular lesions appear to respond to standard antiparasitic drug therapies, but continued treatment is probably necessary to prevent reactivation of disease in the most immunocompromised patients. The best treatment regimens have yet to be determined. Histopathologic studies show little retinal inflammation; therefore anti-inflammatory drugs, such as oral steroids, probably have no role in the management of infection.

Entities:  

Mesh:

Year:  1989        PMID: 2697706     DOI: 10.1007/BF02306488

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  19 in total

1.  Editorial: Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy.

Authors:  G R O'Connor; J K Frenkel
Journal:  Arch Ophthalmol       Date:  1976-02

2.  Toxoplasmosis in patients receiving immunosuppressive therapy.

Authors:  S N Cohen
Journal:  JAMA       Date:  1970-01-26       Impact factor: 56.272

3.  Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy.

Authors:  D H Nicholson; E B Wolchok
Journal:  Arch Ophthalmol       Date:  1976-02

4.  Retinal manifestations of the acquired immune deficiency syndrome (AIDS): cytomegalovirus, candida albicans, cryptococcus, toxoplasmosis and Pneumocystis carinii.

Authors:  J S Schuman; A H Friedman
Journal:  Trans Ophthalmol Soc U K       Date:  1983

5.  Ocular toxoplasmosis and Hodgkin's disease: report of two cases.

Authors:  B Hoerni; M Vallat; M Durand; D Pesme
Journal:  Arch Ophthalmol       Date:  1978-01

6.  Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers.

Authors:  B Wong; J W Gold; A E Brown; M Lange; R Fried; M Grieco; D Mildvan; J Giron; M L Tapper; C W Lerner
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

7.  Opportunistic toxoplasmic retinochoroiditis following chemotherapy for systemic lymphoma. A light and electron microscopic study.

Authors:  J H Yeo; F A Jakobiec; T Iwamoto; G Richard; I Kreissig
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

8.  Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome.

Authors:  B J Luft; R G Brooks; F K Conley; R E McCabe; J S Remington
Journal:  JAMA       Date:  1984-08-17       Impact factor: 56.272

Review 9.  The retinal lesions of the acquired immune deficiency syndrome.

Authors:  A H Friedman
Journal:  Trans Am Ophthalmol Soc       Date:  1984

10.  Bilateral toxoplasma retinochoroiditis in a patient with acquired immune deficiency syndrome.

Authors:  M H Heinemann; J M Gold; J Maisel
Journal:  Retina       Date:  1986       Impact factor: 4.256

View more
  11 in total

1.  Severe bilateral necrotising retinitis caused by Toxoplasma gondii in a patient with systemic lupus erythematosus and diabetes mellitus.

Authors:  J H Yamamoto; D I Boletti; Y Nakashima; C E Hirata; E Olivalves; M M Shinzato; T S Okay; R M Santo; M I S Duarte; J Kalil
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

Review 2.  Toxoplasma gondii and ocular toxoplasmosis: pathogenesis.

Authors:  C E Pavesio; S Lightman
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

3.  Activation of toxoplasma retinochoroiditis during pregnancy and evaluation of ocular findings in newborns.

Authors:  Fatih Mehmet Türkcü; Alparslan Şahin; Harun Yüksel; Yasin Çınar; Kürşat Cingü; Suat Altındağ; Özcan Deveci; Zeynep Özkurt; İhsan Çaça
Journal:  Int Ophthalmol       Date:  2016-08-01       Impact factor: 2.031

4.  Recurrence rates of ocular toxoplasmosis during pregnancy.

Authors:  Arthur M D Braakenburg; Catherine M Crespi; Gary N Holland; Sheng Wu; Fei Yu; Aniki Rothova
Journal:  Am J Ophthalmol       Date:  2014-01-09       Impact factor: 5.258

5.  Utility of tissue culture for detection of Toxoplasma gondii in vitreous humor of patients diagnosed with toxoplasmic retinochoroiditis.

Authors:  D Miller; J Davis; R Rosa; M Diaz; E Perez
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 6.  [Acute retinal necrosis].

Authors:  A Gandorfer; S Thurau
Journal:  Ophthalmologe       Date:  2009-08       Impact factor: 1.059

7.  Detection of Toxoplasma gondii in aqueous humour by the polymerase chain reaction.

Authors:  F Aouizerate; J Cazenave; L Poirier; P Verin; A Cheyrou; J Begueret; F Lagoutte
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

Review 8.  Toxoplasmosis, old stories and new facts.

Authors:  F van Knapen
Journal:  Int Ophthalmol       Date:  1989-12       Impact factor: 2.031

9.  Evaluation of risk and diagnostic value of quantitative assays for anti-Toxoplasma gondii immunoglobulin A (IgA), IgE, and IgM and analytical study of specific IgG in immunodeficient patients.

Authors:  J M Pinon; F Foudrinier; G Mougeot; C Marx; D Aubert; O Toupance; G Niel; M Danis; P Camerlynck; G Remy
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

10.  Ca2+ entry at the plasma membrane and uptake by acidic stores is regulated by the activity of the V-H+ -ATPase in Toxoplasma gondii.

Authors:  Andrew J Stasic; Eric J Dykes; Ciro D Cordeiro; Stephen A Vella; Mojtaba S Fazli; Shannon Quinn; Roberto Docampo; Silvia N J Moreno
Journal:  Mol Microbiol       Date:  2021-04-19       Impact factor: 3.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.